65025-95-8

Basic information

• Product Name: 4-(T-BUTYLDI-ME-SIO-ME)HEXA-H-5-(T-H-PYR AN -2-YLOXY)-CYCLOPENTA(B)FURAN-2-ON, 97
• Synonyms: 4-(T-BUTYLDI-ME-SIO-ME)HEXA-H-5-(T-H-PYR AN -2-YLOXY)-CYCLOPENTA(B)FURAN-2-ON, 97;(3aR,4S,5R,6aS)-(?-(tert-Butyldimethylsilyloxymethyl)hexahydro-5-(tetrahydro-2H-pyran-2-yloxy)-2H-cyclopenta[b]furan-2-one;4-(T-butyldi-me-sio-me)hexa-H-5-(T-H-pyran -2-ylo;(3aR,4S,5R,6aS)-(-)-(tert-Butyldimethylsilyloxymethyl)hexahydro-5-(tetrahydro-2H-pyran-2-yloxy)-2H-cyclopenta[b]furan-2-one;(3aR,4S,5R,6aS)-4-[[[(1,1-Dimethylethyl)dimethylsilyl]oxy]methyl]hexahydro-5-[(tetrahydro-2H-pyran-2-yl)oxy]-2H-cyclopenta[b]furan-2-one;2H-Cyclopenta[b]furan-2-one,4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]hexahydro-5-[(tetrahydro-2H-pyran-2-yl)oxy]-,(3aR,4S,5R,6aS)-;(3aR,4S,5R,6aS)-4-(tert-Butyldimethylsilyloxy)methyl-5-tetrahydropyranyloxy-hexahydro-2H-cyclopenta[b]furan-2-one;[3aR-(3aα,4α,5β,6aα)]-4-[[[(1,1-DiMethylethyl)diMethylsilyl]oxy]Methyl]hexahydro-5-[(tetrahydro-2H-pyran-2-yl)oxy]-2H-cyclopenta[b]furan-2-on
• CAS NO: 65025-95-8
• Molecular Formula: C₁₉H₃₄O₅Si
• Molecular Weight: 370.55576
• EINECS: 1312995-182-4
• Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 65025-95-8.mol
• Article Data: 12

Chemical Properties

• Melting Point: 40-53 °C(lit.)
• Flash Point: 113 °C
• Appearance: /
• Density: 1.07
• Refractive Index: 1.488
• Storage Temp.: 2-8°C
• Solubility: Acetone, Chloroform, Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: 4-(T-BUTYLDI-ME-SIO-ME)HEXA-H-5-(T-H-PYR AN -2-YLOXY)-CYCLOPENTA(B)FURAN-2-ON, 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(T-BUTYLDI-ME-SIO-ME)HEXA-H-5-(T-H-PYR AN -2-YLOXY)-CYCLOPENTA(B)FURAN-2-ON, 97(65025-95-8)
• EPA Substance Registry System: 4-(T-BUTYLDI-ME-SIO-ME)HEXA-H-5-(T-H-PYR AN -2-YLOXY)-CYCLOPENTA(B)FURAN-2-ON, 97(65025-95-8)

Safety Data

• Hazardous Substances Data: 65025-95-8(Hazardous Substances Data)

Usage

Uses

Intermediate in the preparation of prostaglandin derivatives

InChI:InChI=1/C19H34O5Si/c1-19(2,3)25(4,5)22-12-14-13-10-17(20)23-15(13)11-16(14)24-18-8-6-7-9-21-18/h13-16,18H,6-12H2,1-5H3/t13-,14-,15+,16-,18?/m1/s1

Upstream product

• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 110-87-2 3,4-dihydro-2H-pyran 
• 62939-82-6 (3aR,4S,5R,6aS)-5-(acetyloxy)-4-[(acetyloxy)methyl]hexahydro-2H-cyclopenta[b]furan-2-one 
• 26054-46-6 (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one 
• 288-32-4 1H-imidazole 
• 69222-61-3 2-oxo-6-syn-(hydroxymethyl)-7-anti-(tetrahydropyran-2-yloxy)-cis-bicyclo<3.3.0>octan-3-one 
• 62447-84-1 (3aR,4S,5S,6R,6aR)-4-Benzyloxymethyl-6-iodo-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 31767-37-0 6-Benzyloxymethyl-7-hydroxy-8-iodo-2-oxabicyclo<3.3.0>octan-3-one 
• 32233-38-8 3α,5α-dihydroxy-2β-(benzyloxymethyl)cyclopentane-1α-acetic acid γ-lactone 3-tetrahydropyran-2-yl ether 
• 165876-61-9 (3aR,4S,5R,6aS)-4-((tert-butyldimethylsilyloxy)methyl)-2-oxo hexahydro-2H-cyclopenta[b]furan-5-yl biphenyl-4-carboxylate 
• 31752-99-5 (-)-Corey lactone 5-(4-phenylbenzoate) 
• 58707-50-9 (3aR,4S,5R,6aS)-4-((tert-butyldimethylsilyloxy)methyl)-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one 

Downstream Products

• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 67788-45-8 (1S,5R,6S,7R)-7-(tetrahydropyran-2-yl)oxy-6-(tetrahydropyran-2-yl)oxymethyl-2-oxabicyclo[3.3.0]octan-3-one 
• 1431141-69-3 (1S,2R,3R,4S)-2-(2-hydroxyethyl)-3-(hydroxymethyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclopentanol 
• 1431141-72-8 (1S,2R,3S,4R)-4-(tert-butyldimethylsilyloxy)-2-(2-(tert-butyldimethylsilyloxy)ethyl)-3-((tert-butyldimethylsilyloxy)methyl)cyclopentyl4-methylbenzenesulfonate 
• 1431141-74-0 (1R,2S,3R,4R)-3-(2-hydroxyethyl)-2-(hydroxymethyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)cyclopentanol 
• 1431141-67-1 (1R,2S,3R,4S)-4-(tert-butyldimethylsilyloxy)-3-(2-(tert-butyldimethylsilyloxy)ethyl)-2-((tert-butyldimethylsilyloxy)methyl)cyclopentyl-4-methylbenzenesulfonate 
• 88852-12-4 limaprost 
• 112168-22-6 [3aS-(3aα,4α,5β,6aα)]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]hexahydro-5-[(tetrahydro-2H-pyran-2-yl)oxy]-2(1H)-pentalenone 
• 1262874-46-3 4-{(5aR,6R,7R,8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid 
• 1262874-45-2 3-{(5aR,6R,7R,8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl}propanoic acid 

Relevant articles and documents

Discovery of novel seven-membered prostacyclin analogues as potent and selective prostaglandin FP and EP3 Dual Agonists

A novel series of prostaglandin analogues with a seven-membered ring scaffold was designed, synthesized, and evaluated for the functional activation of prostaglandin receptors to identify potent and subtype-selective FP and EP3 dual agonists. Starting fro

A process for the preparation of intermediates useful in the ruby's forefront, preparation method thereof and through its preparation ruby's forefront method

The invention relates to an intermediate for preparing lubiprostone, a preparation method of the intermediate and a method for preparing the lubiprostone through the intermediate, in particular to a compound as shown in a formula V for preparing the lubiprostone (as shown in a formula I), a preparation method of the compound and a method for preparing the lubiprostone through the compound. The method comprises the following steps: performing reduction treatment on the compound as shown in the formula V, performing selective deprotection and hydroxyl oxidation to obtain a compound as shown in a formula II, and performing hydroxyl deprotection on the compound as shown in the formula II to prepare the lubiprostone as shown in the formula I. The method is easy and convenient to operate, high in synthetic yield and suitable for large-scale production.

BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

Provided is a compound which has strong intraocular pressure lowering action and has no side effect on eyes such as ocular stimulating property, humor protein rise etc. Since a compound represented by the formula (I): (wherein definition of each group is